SCHEMBL627989

SCHEMBL627989

Cc1ccc2c(c1)N(C)c1ccccc1S2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.70
NOX1 Q9Y5S8 5/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
LMNA P02545 2/20 0.59
MAPT P10636 2/20 0.59
MAPK1 P28482 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
ADRA2A P08913 1/20 0.57
ADRA2B P18089 1/20 0.57
ADRA2C P18825 1/20 0.57
CHRM3 P20309 1/20 0.57
SLC6A2 P23975 1/20 0.57
HTR2C P28335 1/20 0.57
SLC6A4 P31645 1/20 0.57
DRD3 P35462 1/20 0.57
HTR2B P41595 1/20 0.57
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11927569 0.90 MAOA (0.52) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL628765 0.89 MAOA (0.70) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL2756770 0.87 NOX1 (0.50) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL29377505 0.84 MAOA (1.00) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL231247 0.84 MAOA (1.00) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL11381973 0.82 MAOA (0.59) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL23954309 0.80 MAOA (0.68) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL628328 0.80 MAOA (0.68) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL16810782 0.80 MAOA (0.68) MAOANOX1L3MBTL1LMNAMAPT
SCHEMBL9395281 0.80 MAOA (0.68) MAOANOX1L3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1883987-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M Innovative Properties Company (US) 2008-02-06 EP claimed
WO-2006124738-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-23 WO claimed
US-20060263697-A1 Substituted phenothiazine redox shuttles for rechargeable lithium-ion cell 3M INNOVATIVE PROPERTIES COMPANY 2006-11-23 US claimed
WO-2022109329-A1 TRICYCLIC COMPOUNDS AND RELATED COMPOSITIONS, ZINC ELECTROCHEMICAL CELLS, BATTERIES, METHODS AND SYSTEMS ALIONYX ENERGY SYSTEMS (US) 2022-05-27 WO disclosed
US-20130184258-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 US disclosed
US-8309543-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-13 US disclosed
US-8278298-B2 Prophylaxis, therapy of Alzheimer's disease, Pick's disease; administering phenothiazine compound such as methylene blue WISTA LABORATORIES LTD. (SG) 2012-10-02 US disclosed
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
EP-1883987-B1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES CO (US) 2012-02-22 EP disclosed
US-20090260686-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-10-22 US disclosed
EP-2110376-A1 Novel compounds for electronic material and organic electronic device using the same Gracel Display Inc. (KR) 2009-10-21 EP disclosed
US-20090230852-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-09-17 US disclosed
US-20090170934-A1 MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC NICOX SA 2009-07-02 US disclosed
US-20090048219-A1 ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC. (US) 2009-02-19 US disclosed
EP-1883987-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M Innovative Properties Company (US) 2008-02-06 EP disclosed
US-20060263697-A1 Substituted phenothiazine redox shuttles for rechargeable lithium-ion cell 3M INNOVATIVE PROPERTIES COMPANY 2006-11-23 US disclosed
WO-2006124738-A1 SUBSTITUTED PHENOTHIAZINE REDOX SHUTTLES FOR RECHARGEABLE LITHIUM-ION CELL 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-23 WO disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090260686-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, FZD7 MAOA 518/4885NOX1 48/4885L3MBTL1 1237/4885
US-20090048219-A1 ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NOS3, NOS1, NOS2 MAOA 1219/4885NOX1 14/4885L3MBTL1 3793/4885
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS SCNN1G, KCNN3, KCNN2 MAOA 1439/4885NOX1 1522/4885L3MBTL1 4236/4885
US-20090230852-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OXER1, L1CAM, RPL41 MAOA 1764/4885NOX1 95/4885L3MBTL1 479/4885
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels SCNN1G, KCNN3, KCNN2 MAOA 1439/4885NOX1 1522/4885L3MBTL1 4236/4885
US-20130184258-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 MAOA 1439/4885NOX1 1522/4885L3MBTL1 4236/4885
US-20090170934-A1 MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC NOS2, NOS1, NOS3 MAOA 297/4885NOX1 573/4885L3MBTL1 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.